Company intelligence / Profile preview

NuProbe

Houston, Texas, United Statesnuprobe.com ↗

Ownership: Private
Employees: ~62
Development stage: Commercial

Overview

NuProbe has developed ultrasensitive genomics panels and diagnostic platforms that significantly improve the sensitivity of detecting low-frequency mutations, gene fusions, and CNVs. Their technologies have been validated in pilot studies with strong results in oncology liquid biopsy applications.

Therapeutic areas: OncologyOther
Modalities: Device (diagnostic assay panels)
Industry: Molecular Diagnostics

Drug pipeline

2 assets

VarTrace MSI qPCR Assay

Commercial

Indications: Cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Bio-Rad – exclusive licensing agreement for digital PCR applications using allele enrichment technologies from NuProbe USAANGLE plc – exclusive agreement to commercialize a pan-cancer NGS panel for CTC-DNA analysis

Beyond the preview

Go deeper on NuProbe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuProbe.

Explore the full profile